ZSP1225 GLP-1/GIP Dual Agonist Receives IND Approval for Fourth Indication: Obesity with Obstructive Sleep Apnea

January 23, CDE official website shows, Zhongsheng PharmaceuticalRAY1225 Injection Approved for Clinical Use, for the TreatmentObesity with Obstructive Sleep Apnea（OSA）. This is the fourth approved clinical indication for the product, the others being respectivelyObesity, Type 2 Diabetes andMetabolic Dysfunction-Associated Steatohepatitis。

RAY1225 is an innovative structured peptide drug independently developed by raynovent, with global intellectual property rights.GLP-1 Receptor and GIP ReceptorDual agonist activity can promote insulin secretion and inhibit glucagon in a glucose-dependent manner to control blood sugar, while also inhibiting gastric emptying, suppressing appetite, reducing body weight, decreasing peripheral insulin resistance, and improving hepatic steatosis and ballooning, etc. Thanks to excellent pharmacokinetic properties,RAY1225 PossessInject once every two weeksThe ultra-long-acting drug potential.

RAY1225 is conducting 3 Phase III studies, all of which have successfully completed the enrollment of all subjects, respectively:

• Phase III Clinical Trial for the Safety and Efficacy of Treating Obese/Overweight Patients in China(REBUILDING-2 Study)；

• Safety and Efficacy of Combination Therapy with Oral Hypoglycemic Agents in Patients with Type 2 DiabetesSemaglutide Injection ControlPhase III Clinical Trial(SHINING-3 Study)；

• Safety and Efficacy of Monotherapy in Patients with Type 2 Diabetes Mellitus, Placebo-Controlled Phase III Clinical Trial(SHINING-2 Study)。

2026January, ZhongshengRaynovent Collaborates with Qilu PharmaceuticalThe rights for production and commercial sales of RAY1225 in China are granted to the latter.The total transaction amount is as high as 1 billion yuan., of which the down payment is 200 million yuan.

Cover Source:Corporate Logo

Disclaimer:This article is for information sharing only, and does not represent the position or viewpoint of Insight. It does not recommend or introduce any treatment plans. If necessary, please consult and contact正规医疗机构.

Editor: Crescent

PR Article Collaboration: WeChat insightxb